BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Generalized Lipodystrophy readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Generalized Lipodystr
 ophy\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07220785-147@assetmemo.bio
DTSTAMP:20261121T004448Z
DTSTART;VALUE=DATE:20280519
DTEND;VALUE=DATE:20280520
SUMMARY:mibavademab: Phase 3 readout est. (NCT07220785)
DESCRIPTION:mibavademab\, phase 3\, Generalized Lipodystrophy.\nStudy: Effi
 cacy and Safety of Mibavademab in Adult and Pediatric Patients With Genera
 lized Lipodystrophy\nEstimated primary completion: 19 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/mibavademab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07220785
URL:https://assetmemo.bio/drug/mibavademab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
